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Summary The aim of the present study was to demonstrate an equivalent asthma
control and safety of inhaled budesonide 200 mg unit-dose via a spacer device (Jets
Spacer, Chiesi Farmaceutici S.p.A.) given with an HFA-134a or CFC propellant in stable
patients treated with inhaled corticosteroids. A total number of 270 patients, 134 in
the HFA-134a group and 136 in the CFC group, completed a 2-week run-in period and
were then randomised to receive a daily dose of inhaled budesonide (low dose:
400 mg, medium dose: 800 mg, high dose: 1200 or 1600 mg), defined on the basis of the
dose of previous inhaled steroids given twice daily for 12 weeks. Morning and evening
PEFR, intake of rescue salbutamol, number of day-time and night-time asthma
attacks, number of night-time awakenings due to asthma and clinical symptoms were
recorded daily by patients on diary cards. Pulmonary function tests (FEV1, FVC, PEFR
and MEF50) and vital signs were measured at the clinics at study entry, at the start of
treatment and after 2, 4, 8 and 12 weeks thereafter. Morning serum cortisol (8.00–
10.00 AM) was measured at baseline and in the final visit. Adverse events and vital
signs were recorded throughout the total study period.
Small increases vs. baseline for lung function (more markedly in the high-dose
subsets) and significant decreases of symptoms and use of rescue salbutamol were
similarly observed in both groups. Equivalence was demonstrated for the primary
endpoint morning PEFR (difference between means¼1.51 l/min; 95% CI: 9.40–
6.37 l/min; pre-defined limits:742.16 l/min, i.e.710% of the reference LSM) as well
as for evening PEFR and FEV1, both in the ITT population or on a per-protocol basis. No
statistically significant differences between groups were observed in any of the other
efficacy variables.
A similar proportion of drug-related adverse events was observed in the two groups,
without drug-related serious events in either group. No evidence of adrenal depletion
was also noted with both propellants.
In conclusion, the budesonide HFA-134a formulation given with a spacer device
provided an equivalent asthma control with that of a corresponding CFC product,
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when administered in stable patients treated with inhaled corticosteroids in a broad
range of daily doses. The use of the new propellant did not modify the safety profile
of inhaled budesonide.
& 2003 Published by Elsevier Ltd.
Introduction
The pressurised metered dose inhaler (pMDI) is
currently the device of choice for asthma inhala-
tion therapy, being a well-established safe and
reliable delivery system and the device most widely
used by adults with asthma.1 Pressurised MDIs have
been approved for the administration of virtually
all inhaled drugs used in the treatment of rever-
sible obstructive airways disease. Since the pre-
valence of this disease is increasing both in adults
and children,2,3 there is a rising need for inhaled
therapies in the near future, with national and
international guidelines recommending use of
corticosteroids and bronchodilators for the treat-
ment of asthma and chronic airways’ obstruc-
tion.4,5
Due to the growing awareness that traditional
chlorofluorocarbons (CFCs) contributes to the de-
pletion of stratospheric ozone through the specific
action of their chloride radicals,6 hydrofluoroalk-
ane (HFA)-134a (1,1,1,2-tetrafluoroethane or nor-
flurane) has been developed as a replacement
propellant for use in MDIs since it is chemically
inert, non-flammable and of low toxicity. HFA-134a
has been found to be a suitable alternative to CFCs
used in the formulation of inhaled drugs,7 and this
has been born out by the subsequent development
of re-formulated anti-asthma medicines containing
this propellant, mainly inhaled glucocorticoster-
oids.
Among the currently available inhaled gluco-
corticosteroids, budesonide has a high ratio of
topical to systemic activity compared with other
reference steroids, such as beclometasone dipro-
pionate, which allows inhalation of therapeutic
doses with minimal systemic exposure.8 Recent
in vivo data and human pharmacokinetic/pharma-
codynamic studies have shown that the formation
of budesonide esters may increase the topical
selectivity of budesonide,9 which, in addition to
its prolonged effects, accounts for a once daily
administration. The availability of a CFC-free
formulation of budesonide is therefore expected
to allow a transition from the current pMDI
product.
A new HFA-134a formulation of budesonide has
now been developed by Chiesi Farmaceutici S.p.A.
aimed at maintaining a dose per dose equivalence
with respect to the CFC formulation. The present
study has been therefore designed to investigate
whether the new budesonide HFA-134a, delivered
via pMDI with the addition of a spacer, can provide
an equivalent asthma control and systemic safety
to that of a marketed CFC-formulated budesonide
in a broad range of daily doses administered in
adult patients.
Patients and methods
Patients
Participating subjects were selected in 13 centres,
seven of them were located in Poland, five in Spain
and one in Austria. They had to satisfy all of the
following entry criteria: age X18 and p70 (in-
clusive); clinical diagnosis of mild to severe stable
persistent asthma, well-controlled with inhaled
steroids taken from at least 8 weeks (at a daily
dose equivalent to inhaled budesonide p1600 mg);
responsive to inhaled b2-agonists; ability to cor-
rectly use a pMDI and complete diary cards; written
informed consent. Subjects with evidence of
asthma exacerbation or upper airways infection in
the previous 8 weeks, history of clinically signifi-
cant cardiac, renal, neurologic, hepatic or endo-
crine disease; intake of oral steroids in the previous
8 weeks, or of inhaled corticosteroids at a daily
dose exceeding a corresponding dose of 1600 mg
inhaled budesonide, pregnancy or risk of preg-
nancy, heavy smoking habits (defined as X20
cigarettes/day over a 20-year period) or hypersen-
sitivity to inhaled corticosteroids were excluded
from the participation in the study.
Intake of inhaled salbutamol was permitted at
any time. Long acting b2-agonists, inhaled or oral
sodium cromoglycate or nedocromil sodium, theo-
phyllines and leukotriene antagonists were per-
mitted at a constant dose throughout the study
period only if taken at study entry. Inhaled
corticosteroids could continue being taken during
the run-in period, whereas anticholinergics, oral
corticosteroids, and antihistamines were not per-
mitted at any time.
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Study design, treatment and outcome
measures
This was a double blind, randomised, multina-
tional, multicentre, parallel-group design study.
Patients were divided into three treatment/dose
subsets (low, medium and high dose) based on the
daily dose of inhaled corticosteroids taken at study
entry, once taken into account the following ratios
between the doses of other steroids and budeso-
nide, irrespectively of the formulations (i.e.
pMDI or powder) used: fluticasone propionate:
budesonide¼ 1:2; beclometasone dipropionate:
budesonide¼ 5:4. Patients treated at a low dose
(p400 mg/day budesonide equivalent) were as-
signed to 400 mg/day, those treated at a medium
dose (4400 and p800 mg/day budesonide equiva-
lent) were assigned to 800 mg/day and those
treated at a high dose (4800 mg/day budesonide
equivalent) were assigned to 1200 or 1600 mg/day.
If the calculated dose was not exactly correspond-
ing to the four scheduled dose levels of the test
treatments (for example a dose of 600 mg/day
derived from 750 mg/day beclometasone dipropio-
nate) the assigned dose was the next higher
(800 mg/day in this case).
Eligible patients entered a 2-week run-in period
and were then randomised to start the 12-week
treatment with budesonide 200 mg/unit dose twice
daily via pMDI plus a spacer (Jets Spacer, Chiesi
Farmaceutici S.p.A, Italy, Fig. 1) using the HFA-134a
or the CFC (Ribujets, Chiesi Espa *na, Spain)
propellant.
Thereafter the visits to the clinics took place
after 2, 4, 8 and 12 weeks. At each visit the
following pulmonary function (PF) tests were
performed: forced expiratory volume in one second
(FEV1, l), forced vital capacity (FVC, l), peak
expiratory flow rate (PEFR, l/min), mid expiratory
flow at 50% vital capacity (MEF50, l/s) and the FEV1/
FVC ratio. Three consecutive tests were performed
and the highest FEV1 reading was recorded. If
salbutamol or long-acting b2-agonists had been
used at home, a minimum of 6 and 12 h, respec-
tively, had to have elapsed between inhalation and
PF measurement. Measuring conditions, equipment
and daily calibration of the instrument were
standardised as recommended by the European
Respiratory Society Guidelines.10 Patients also
measured their PEFR (l/min) twice daily (morning
and evening at 08.00 AM and 08.00 PM, respec-
tively) using a portable peak flow meter (Mini-
Wrights, Markos, Italy); the best of three con-
secutive flows was recorded. Daily PEFR variability
was also calculated using the following formula:11
[PEFR eveningPEFR morning/1/2 (PEFR eveningþ
PEFR morning)] 100.
Intake of rescue salbutamol (number of puffs/
day) was recorded daily by patients in a diary card,
as well as the number of day-time and night-time
asthma attacks and the number of night-time
awakenings caused by asthma. Clinical symptoms
(dyspnoea, tachypnoea, wheezing and cough)
were also measured daily using a 4-point rating
scale (where 0¼ none; 1¼mild; 2¼moderate;
3¼ severe) to obtain a global sum of scores. The
percentages of salbutamol-free days and symp-
toms-free days were also evaluated.
A blood sample was taken from an antecubital
vein between 08.00 and 10.00 AM at the start and
at the end of treatment phase for the measurement
of morning serum cortisol levels. Assays were
centralised at Interlab, Heidelberg, Germany, and
were done using luminescence enzyme immunoas-
say (ACS: 180 Cortisol, Chiron Diagnostics, Ger-
many): the range of normal values was set at 5–
25 mg/100ml.
Pulse and blood pressure were measured at each
visit. Patients reported adverse events at each
clinic visit, together with their severity, outcome
and correlation with the study treatments. Com-
pliance was evaluated with the use of diary card
recordings of the administered doses; the propor-
tion of the administered drug was then calculated
with a limit for a satisfactory compliance set at 75%
of scheduled.
Ethics
The study protocol, patient information leaflet and
informed consent document were reviewed and
approved by the Independent Ethics Committees of
each participating centre prior to the start of the
study.
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Figure 1 The Jets Spacer.
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Statistics
The sample size was calculated on the criteria of
the equivalence efficacy between the two test
treatments: it was based on an expected mean
morning PEFR final value (last 2-week period) of
400 l/min and a standard deviation (SD) of 95 l/min
in the CFC group, a power equal to 80% and type I
error a¼ 0.025. The sample size was therefore set
at 120 evaluable patients per group.12 Equivalence
was proven if the bilateral 95% confidence interval
(CI) for the difference between treatment means
fell within the range of710% of the adjusted least-
squares means (LSMs) of the BDP CFC group,
obtained from an ANCOVA model using baseline
values as covariate. Equivalence test between the
two treatments was to be done for morning and
evening PEFR, as well as for FEV1, whereas the
other PF tests, daily PEFR variability, salbutamol
daily use, days without use of salbutamol, asthma
attacks, clinical symptoms, symptoms-free days,
morning serum cortisol and vital signs were
analysed by calculating the 95% CI for the mean
change from baseline; an ANCOVA model was used
for between-group comparisons.
Baseline data was that derived from the mean
values of the 2-week run-in period for variables
recorded on the diary cards and data measured at
the 2nd clinic visit. Two-weekly means were also
calculated for the variables recorded in the diary
cards.
All randomised patients with post-baseline data
were included in the intention-to-treat (ITT)
analysis; patients with major protocol violations
were excluded from the per-protocol (PP) popula-
tion. The last observation carried forward (LOCF)
method was used to deal with missing data.
Results
Patients’ disposition and baseline data
A total number of 280 patients were recruited into
the study: 10 (3.6%) of them were withdrawn during
run-in and 270 were randomised to receive study
medication, 134 in the HFA-134a group and 136 in
the CFC group. Only one patient in the CFC group
did not have post-baseline data and was therefore
excluded from the ITT population. The number of
patients completing the 12-week study period was
127 (94.8%) in the HFA-134a group and 131 (96.3%)
in the CFC group.
Major protocol violations were reported in 28
patients in total, 10 (7.5%) in the HFA-134a group
and 18 (13.3%) in the CFC group, and mainly
consisted of poor compliance (intake of less
than 75% of scheduled drug) and treatment
with a daily dose of inhaled corticosteroids at
study entry exceeding the permitted limit (i.e.
fluticasone 1000 mg/day, corresponding to budeso-
nide 2000 mg/day, above the maximum 1600 mg/day
scheduled dose). The per-protocol population was
therefore made of 124 patients in the HFA group
and of 117 in the CFC group.
The distribution of patients in the three dose
subsets was well matched in the two groups: in the
HFA-134a group, 47 patients (35.1%) were assigned
to the low dose, 47 (35.1%) to the medium dose and
40 (29.8%) to the high dose; in the CFC group, 43
patients (31.8%) were assigned to the low dose, 48
(35.6%) to the medium dose and 44 (32.6%) to the
high dose.
All patients were treated at study entry and
during run-in with their own routine inhaled
corticosteroids: the majority of patients were
taking budesonide, 104 (77.6%) in the HFA-134a
and 92 (68.1%) in the CFC group, while the remain-
ing took fluticasone (10.4% in the HFA-134a and
19.3% in the CFC group) or beclometasone dipro-
pionate (11.9% in the HFA-134a and 12.6% in the
CFC group). In addition, most patients were taking
long acting b2-agonists (70.9% in the HFA-134a
group and 75.6% in the CFC group), which were
continued at constant doses during the 12-week
treatment period.
The baseline details are presented in Table 1.
The two groups were well matched with respect to
demographic and other baseline characteristics,
including the duration of asthma.
The mean FEV1 predicted normal values (%) at
screening in the HFA-134a group were 81.1716.0,
86.0711.8, 81.8716.8 and 74.5717.6 in the total
population, low, medium and high dose subsets,
respectively, whereas the corresponding values in
the CFC group were 83.2718.9, 89.5720.4,
83.9715.7 and 76.2718.7.
Efficacy
The results of the primary variable mean morning
PEFR, and of evening PEFR recorded daily by
patients and FEV1 are presented in Figs. 2, 3 and
4 respectively, both as total population and in the
three dose subsets (ITT population).
The LSMs for morning PEFR (AM PEFR in the last 2
weeks) in the total population were 420.0 l/min in
the HFA-134a group and 421.6 l/min in the CFC
group, with a difference of 1.51 l/min. Statistical
analysis showed that budesonide HFA-134a was
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equivalent to CFC: the bilateral 95% CI for the
treatment difference was 9.40 to 6.37 l/min, well
within the pre-defined equivalence limit of
742.16 l/min (10% of the reference LSM). Small
dose-related increases of morning PEFR in the final
2-week period were reported in both groups (Fig.
2): the comparison between subsets did not show
statistically significant differences (low dose,
P¼ 0.291, intermediate dose, P¼ 0.436, high dose,
P¼ 0.313).
Results of evening PEFR (Fig. 3) were similar to
that obtained in the morning: the LSMs in the total
population were 429.7 l/min for Budesonide HFA-
134a and 430.5 l/min for CFC, with a difference of
0.76 l/min; the bilateral 95% CI for the treatment
difference was 8.62 to 7.10 l/min, within the
equivalence interval of743.05 l/min. The compar-
ison between subsets did not show statistically
significant differences (low dose, P¼ 0.588, inter-
mediate dose, P¼ 0.483, high dose, P¼ 0.430).
As regards to FEV1, increases over baseline were
also more marked in the two high-dose subsets: the
LSMs in the total population were 2.73 l in both
groups, and the bilateral 95% CI for the treatment
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Figure 2 Morning PEFR (l/min) expressed as 2 weekly means (K, HFA-134a; J, CFC), ITT population.
Table 1 Characteristics of the patients’ population at study entry (ITT population).
HFA-134a (n¼ 134) CFC (n¼ 135)
Sex
Males (n) 55 (41.0%) 56 (41.5%)
Females (n) 79 (59.0%) 79 (58.5%)
Age, years (mean7SD) 42.1713.4 42.3714.3
Height, cm (mean7SD) 167.379.1 166.7710.3
Weight, kg (mean7SD) 72.9714.6 73.6714.5
Duration of asthma, years (mean7SD) 13.1710.0 13.8710.4
Morning PEFR, l/min (mean7SD) 413.7794.7 418.97112.6
Evening PEFR, l/min (mean7SD) 422.1789.9 427.47111.4
FEV1 predicted, % (mean7SD) 81.1716.0 83.2718.9
Assigned dose of treatment test
Low dose (n) 47 (35.1%) 43 (31.8%)
Medium dose (n) 47 (35.1%) 48 (35.6%)
High dose (n) 40 (29.8%) 44 (32.6%)
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difference was 0.08 to 0.08 l, again well within
the 70.27 l equivalence interval. The comparison
between subsets did not show statistically signifi-
cant differences (low dose, P¼ 0.459, intermediate
dose, P¼ 0.874, high dose, P¼ 0.756).
Results obtained in the PP population (data not
shown) for the above variables were consistent
with those observed in the ITT analysis.
Other PF tests (FVC, PEFR and MEF50) were
measured at clinic visits. Statistically significant
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Figure 3 Evening PEFR (l/min) expressed as 2 weekly means (K, HFA-134a; J, CFC), ITT population.
Figure 4 FEV1 (l) during the study (K, HFA-134a; J, CFC), ITT population.
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increases over baseline for all parameters were
observed from week 8 onwards in both groups,
without significant differences between them. No
substantial changes in both groups were also
reported for daily PEFR variability and in the
FEV1/FVC ratio (data not shown).
Results of rescue salbutamol intake, asthma
attacks and awakenings, and symptoms’ scores
are shown in Table 2.
A progressive and statistically significant im-
provement over time of asthma control (symptoms’
scores, symptom-free days, day-time and night-
time asthma attacks, asthma-induced nocturnal
awakenings) was similarly observed in both groups.
The daily use of rescue salbutamol and the number
of days without salbutamol intake was therefore
significantly reduced over time in both groups. The
comparison between groups did not show any
significant difference for any of the above para-
meters.
Safety
The individual data of morning serum cortisol in
patients with both baseline and final sample are
shown in Fig. 5. The overall mean values in the
total population showed a small decrease in both
groups (0.46 mg/100ml in the HFA-134a and
0.19 mg/100ml in the CFC group), without sig-
nificant differences between groups (P¼ 0.248).
The mean change from baseline in the low-dose
subset showed a small increase in the HFA-134a
group (þ 0.43 mg/100ml) and a small decrease in
the CFC group (0.72 mg/100ml); a small increase
in both groups was observed in the medium-dose
(0.60 mg/100ml in the HFA-134a and 0.53 mg/
100ml in the CFC group), whereas a decrease in the
HFA-134a group (1.33 mg/100ml) and an increase
in the CFC group (þ 0.77 mg/100ml) were noted in
the high-dose subset. In the HFA-134a group, six
patients had a decrease of normal baseline levels
below the lower limit of normal range, whereas 11
patients had a normalisation of low baseline levels;
in the CFC group, the corresponding figures were of
two and eight patients, respectively.
A total of 28 drug-related (with definite, prob-
able, possible or doubtful relationship to study
medication) adverse events were reported during
the study, with 17 in the HFA-134a group and 11 in
the CFC group, and they occurred in 27 patients in
total, 16 (11.9%) and 11 (8.1%) in the two groups,
respectively. The most commonly affected body
system was the respiratory tract; other drug-
related events included local effects (hoarseness
or disphonia/aphonia, but without cases of myco-
sis), changes of serum cortisol levels, cardiovascu-
lar effects (tachycardia, blood pressure elevation)
and unpleasant taste (in two patients treated
with HFA-134a). A total of four patients (1.5%),
two in each group, discontinued the study
due to adverse events: critical elevation of blood
pressure and dysphonia in the HFA-134a group and
aphonia in the CFC group. Only one serious AE was
reported in one patient in the HFA-134a group (high
blood pressure), which was of a moderate severity
and was considered as not related with the study
drug.
No clinically significant changes occurred in vital
signs (heart rate and blood pressure). The com-
pliance profile was excellent in both groups: the
mean reported intake was 96.3% in the HFA-134a
group and 94.4% in the CFC group.
Discussion
The budesonide HFA-134a formulation used in the
present study has been developed by adding
glycerol as low solvent to the standard ethanol
excipient and acting on the actuator’s orifice
diameter,13 with the aim to obtain a particle size
distribution similar to that of the CFC-fomulated
budesonide, thereby allowing a dose per dose
transition from the existing product. In fact, the
earliest inhaled corticosteroids formulated with
CFC-free propellants (e.g. beclometasone dipro-
pionate) were developed as ultrafine aerosol with a
halved dose,14 whereas it has been shown that
fluticasone propionate HFA-134a pMDI is compar-
able to the corresponding CFC at a microgram
equivalent dose.15,16
The objective of the present study was therefore
to demonstrate equivalent asthma control and
safety between budesonide using a HFA-134a and
a CFC propellant, both drugs being administered via
the Jets Spacer, in a broad range of doses. The two
treatment groups were equally divided in three
randomised subsets, treated with a low (400 mg/
day), medium (800 mg/day) or high (1200 or
1600 mg/day) dose, based on the dose of inhaled
corticosteroids taken at study entry and during run-
in. To exclude any potential carry-over effect due
to the previous corticosteroids, the main compar-
isons were done with outcome measures collected
at the end of the 12-week treatment period. The
two groups and the three subsets were well
matched for asthma severity (FEV1% predicted)
and baseline values of all efficacy and safety
parameters; the severity of asthma was also dose-
related.
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Table 2 Clinical parameters daily recorded on diary cards (ITT population).
Treatment Baseline
(mean7SD)
Weeks 1–2
(mean7SD)
Weeks 3–4
(mean7SD)
Weeks 5–6
(mean7SD)
Weeks 7–-8
(mean7SD)
Weeks 9–10
(mean7SD)
Weeks 11–12
(mean7SD)
Clinical symptom score HFA-134a 2.2672.06 2.2272.09 2.0972.04 1.9071.99 1.8672.00 1.8371.95 1.7471.81
CFC 2.1472.15 1.9772.14 1.6771.77 1.7271.97 1.6671.87 1.5471.79 1.5771.78
Symptoms-free days (%) HFA-134a 31.3737.6 34.0737.5 36.7739.2 39.0739.8 40.0740.8 42.8741.7 40.5740.9
CFC 35.2736.4 41.0740.9 43.0740.6 45.9742.2 44.8742.2 49.1742.7 48.3742.5
Salbutamol consumption (number of puffs) HFA-134a 1.2071.44 1.1371.39 1.1271.39 1.0371.42 1.0071.36 1.0171.45 0.9671.34
CFC 1.3071.83 1.2071.85 1.0971.72 1.1071.71 1.1071.74 1.0471.66 1.0471.65
Day-time asthma attacks (number) HFA-134a 0.5570.69 0.4970.64 0.5070.70 0.4470.67 0.4070.58 0.3770.56 0.3570.56
CFC 0.5971.10 0.5370.99 0.4570.87 0.4470.86 0.4270.84 0.4270.84 0.4270.85
Night-time asthma attacks (number) HFA-134a 0.2470.38 0.2270.37 0.2370.42 0.1870.36 0.1870.38 0.1970.34 0.1670.33
CFC 0.2270.56 0.1970.41 0.1670.33 0.1570.34 0.1670.37 0.1470.32 0.1470.30
Night-time awakenings (number) HFA-134a 0.2170.39 0.2270.41 0.2570.50 0.1970.41 0.1870.40 0.1770.32 0.1570.31
CFC 0.2470.65 0.2170.45 0.1570.32 0.1670.39 0.1570.37 0.1370.31 0.1470.28
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Values of pulmonary function tests (both mea-
sured daily by patients and at clinic visits) showed
an overall small improvement from baseline to final
in both groups, without differences between them.
This improvement may be explained on the basis of
a small increase of dose in patients where the daily
dose of the previous corticosteroid was not exactly
reproducible with the 200 mg unit dose, and on the
basis of a maximal adherence to the assigned
therapy. For the primary efficacy measure mean
morning PEFR during the last 2-week period, the
adjusted means were similar for HFA-134a and for
CFC, and the calculated 95% CI for the difference
between the LSMs was well within the pre-defined
limit of 710% of the reference drug. This equiva-
lence limit is also well contained within narrower
ranges (i.e. 30, 25 or 15 l/min), as used in similar
comparative trials.17–19 This was also the case for
all the other endpoints that were used to test
the equivalence, mean evening PEFR and FEV1.
Obviously, the study was powered to show equiva-
lence in the total population and not in each dose
subset; however, data obtained in the three dose
ranges were comparable in the two groups. The
estimated treatment differences in the total
population were also negligible for the other
pulmonary function and no significant differences
between groups were observed. Symptoms (number
of day-time and night-time asthma attacks, number
of nocturnal awakenings, global asthma symptoms’
scores) and use of rescue salbutamol (daily number
of puffs and percentage of salbutamol’s free days)
showed a similar significant improvement in both
groups.
A small non-significant decrease of morning
cortisol levels was observed in both groups;
notably, in both groups the number of patients
with a decrease of final values below the lower
limit of normal range (six in the HFA-134a group and
two in the CFC group) was lower than the number
of patients with baseline values below the normal
limit and restored to normal final values (11 and
eight in the two groups, respectively). The propor-
tion of patients who reported drug-related adverse
events was low in the two groups, with 16 patients
(11.9%) in the budesonide HFA group and 11 (8.1%)
in the CFC-budesonide group; the minimal differ-
ence between groups is mainly caused by two cases
of taste dislike, which is a well-known mild and
transient event in the switching from CFC to
HFAs,20 and by a few cases of cardiovascular events
(blood pressure elevation and tachycardia), which
are more likely to be due to the concomitant use of
b2-agonists than to the inhaled corticosteroid.
The results of the present study have therefore
shown that inhaled budesonide given with the HFA-
134a propellant provides an equivalent asthma
control and similar systemic effects to that of the
CFC formulation. However, it is actually preferred
that in equivalence trials treatments are compared
in the steep part of the dose–response curve;21
therefore, these results should be confirmed in a
sample of patients with a wider room for improve-
ment to that of the present study, which included
subjects with well controlled asthma on their
inhaled steroids dosage. Furthermore, the use of
the Jets Spacer, which is a small-size device with
proven advantages in terms of topical to systemic
effects ratio, may have reduced the possibility to
observe potential differences on the effects on the
hypophysis–pituitary–adrenal axis;22 it would be
therefore advised that the results of the present
trial are confirmed when budesonide HFA-134 is
administered via pMDI only.
We can conclude that the preliminary findings of
the present study show that budesonide HFA-134 is
equivalent to the CFC formulation in a broad range
of doses, when delivered with a spacer device in
adult patients with stable asthma controlled with
inhaled corticosteroids.
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Figure 5 Morning serum cortisol: individual patients’ data (normal range between dotted lines: 5–25 mg/100ml),
completer population. m, low dose; &, medium dose; K, high dose.
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